AEON AEON Biopharma, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1837607 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,587,233.3%
TTM EPS YoY-222.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-416.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets83.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-269.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $4.09M | $14.18M |
| SG&A expense | $12.21M | $13.64M |
| Operating income | -$12.80M | $72.98M |
| Pretax income | -$39.22M | $42.01M |
| Income tax | $0 | $0 |
| Net income | -$39.22M | $42.01M |
| EBITDA | -$12.72M | $73.08M |
| EPS (basic) | -3.95 | 77.74 |
| EPS (diluted) | -3.95 | 72.93 |
| Weighted avg. shares (diluted) | 9.92M | 575,945 |
| Balance sheet | ||
| Cash & equivalents | $3.01M | $13,000 |
| Current assets | $3.40M | $1.59M |
| PP&E, net | $162,000 | $235,000 |
| Total assets | $5.56M | $3.14M |
| Current liabilities | $6.90M | $14.15M |
| Total liabilities | $60.59M | $31.71M |
| Shareholders' equity | -$55.03M | -$28.57M |
| Shares outstanding | 12.11M | 555,511 |
| Cash flow statement | ||
| Operating cash flow | -$17.31M | -$20.29M |
| Capital expenditure | $4,000 | — |
| Free cash flow | -$17.31M | — |
| Investing cash flow | -$4,000 | — |
| Financing cash flow | $20.30M | $15.15M |
| Depreciation & amortization | $78,000 | $97,000 |
| Stock-based compensation | $5.32M | $6.25M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.